Clinical end points and response criteria in mycosis fungoides and Sézary syndrome

A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Elise A. Olsen, Sean Whittaker, Youn H. Kim, Madeleine Duvic, H. Miles Prince, Stuart R. Lessin, Gary S. Wood, Rein Willemze, Marie France Demierre, Nicola Pimpinelli, Maria Grazia Bernengo, Pablo L. Ortiz-Romero, Martine Bagot, Teresa Estrach, Joan Guitart, Robert Knobler, José Antonio Sanches, Keiji Iwatsuki, Makoto Sugaya, Reinhard Dummer & 15 others Mark Pittelkow, Richard Hoppe, Sareeta Parker, Larisa Geskin, Lauren Pinter-Brown, Michael Girardi, Günter Burg, Annamari Ranki, Maartan Vermeer, Steven Horwitz, Peter Heald, Steve Rosen, Lorenzo Cerroni, Brigette Dreno, Eric C. Vonderheid

Research output: Contribution to journalArticle

Abstract

Mycosis fungoides (MF) and Sé zary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.

Original languageEnglish (US)
Pages (from-to)2598-2607
Number of pages10
JournalJournal of Clinical Oncology
Volume29
Issue number18
DOIs
StatePublished - Jun 20 2011

Fingerprint

Mycosis Fungoides
Advisory Committees
Lymphoma
Skin
Clinical Trials
Research Personnel
Guidelines
Skin Manifestations
Cutaneous T-Cell Lymphoma
Non-Hodgkin's Lymphoma
Lymph Nodes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical end points and response criteria in mycosis fungoides and Sézary syndrome : A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. / Olsen, Elise A.; Whittaker, Sean; Kim, Youn H.; Duvic, Madeleine; Prince, H. Miles; Lessin, Stuart R.; Wood, Gary S.; Willemze, Rein; Demierre, Marie France; Pimpinelli, Nicola; Bernengo, Maria Grazia; Ortiz-Romero, Pablo L.; Bagot, Martine; Estrach, Teresa; Guitart, Joan; Knobler, Robert; Sanches, José Antonio; Iwatsuki, Keiji; Sugaya, Makoto; Dummer, Reinhard; Pittelkow, Mark; Hoppe, Richard; Parker, Sareeta; Geskin, Larisa; Pinter-Brown, Lauren; Girardi, Michael; Burg, Günter; Ranki, Annamari; Vermeer, Maartan; Horwitz, Steven; Heald, Peter; Rosen, Steve; Cerroni, Lorenzo; Dreno, Brigette; Vonderheid, Eric C.

In: Journal of Clinical Oncology, Vol. 29, No. 18, 20.06.2011, p. 2598-2607.

Research output: Contribution to journalArticle

Olsen, EA, Whittaker, S, Kim, YH, Duvic, M, Prince, HM, Lessin, SR, Wood, GS, Willemze, R, Demierre, MF, Pimpinelli, N, Bernengo, MG, Ortiz-Romero, PL, Bagot, M, Estrach, T, Guitart, J, Knobler, R, Sanches, JA, Iwatsuki, K, Sugaya, M, Dummer, R, Pittelkow, M, Hoppe, R, Parker, S, Geskin, L, Pinter-Brown, L, Girardi, M, Burg, G, Ranki, A, Vermeer, M, Horwitz, S, Heald, P, Rosen, S, Cerroni, L, Dreno, B & Vonderheid, EC 2011, 'Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer', Journal of Clinical Oncology, vol. 29, no. 18, pp. 2598-2607. https://doi.org/10.1200/JCO.2010.32.0630
Olsen, Elise A. ; Whittaker, Sean ; Kim, Youn H. ; Duvic, Madeleine ; Prince, H. Miles ; Lessin, Stuart R. ; Wood, Gary S. ; Willemze, Rein ; Demierre, Marie France ; Pimpinelli, Nicola ; Bernengo, Maria Grazia ; Ortiz-Romero, Pablo L. ; Bagot, Martine ; Estrach, Teresa ; Guitart, Joan ; Knobler, Robert ; Sanches, José Antonio ; Iwatsuki, Keiji ; Sugaya, Makoto ; Dummer, Reinhard ; Pittelkow, Mark ; Hoppe, Richard ; Parker, Sareeta ; Geskin, Larisa ; Pinter-Brown, Lauren ; Girardi, Michael ; Burg, Günter ; Ranki, Annamari ; Vermeer, Maartan ; Horwitz, Steven ; Heald, Peter ; Rosen, Steve ; Cerroni, Lorenzo ; Dreno, Brigette ; Vonderheid, Eric C. / Clinical end points and response criteria in mycosis fungoides and Sézary syndrome : A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 18. pp. 2598-2607.
@article{1ba15e8c77e345bb8f9cc9adc01c7479,
title = "Clinical end points and response criteria in mycosis fungoides and S{\'e}zary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer",
abstract = "Mycosis fungoides (MF) and S{\'e} zary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.",
author = "Olsen, {Elise A.} and Sean Whittaker and Kim, {Youn H.} and Madeleine Duvic and Prince, {H. Miles} and Lessin, {Stuart R.} and Wood, {Gary S.} and Rein Willemze and Demierre, {Marie France} and Nicola Pimpinelli and Bernengo, {Maria Grazia} and Ortiz-Romero, {Pablo L.} and Martine Bagot and Teresa Estrach and Joan Guitart and Robert Knobler and Sanches, {Jos{\'e} Antonio} and Keiji Iwatsuki and Makoto Sugaya and Reinhard Dummer and Mark Pittelkow and Richard Hoppe and Sareeta Parker and Larisa Geskin and Lauren Pinter-Brown and Michael Girardi and G{\"u}nter Burg and Annamari Ranki and Maartan Vermeer and Steven Horwitz and Peter Heald and Steve Rosen and Lorenzo Cerroni and Brigette Dreno and Vonderheid, {Eric C.}",
year = "2011",
month = "6",
day = "20",
doi = "10.1200/JCO.2010.32.0630",
language = "English (US)",
volume = "29",
pages = "2598--2607",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - Clinical end points and response criteria in mycosis fungoides and Sézary syndrome

T2 - A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

AU - Olsen, Elise A.

AU - Whittaker, Sean

AU - Kim, Youn H.

AU - Duvic, Madeleine

AU - Prince, H. Miles

AU - Lessin, Stuart R.

AU - Wood, Gary S.

AU - Willemze, Rein

AU - Demierre, Marie France

AU - Pimpinelli, Nicola

AU - Bernengo, Maria Grazia

AU - Ortiz-Romero, Pablo L.

AU - Bagot, Martine

AU - Estrach, Teresa

AU - Guitart, Joan

AU - Knobler, Robert

AU - Sanches, José Antonio

AU - Iwatsuki, Keiji

AU - Sugaya, Makoto

AU - Dummer, Reinhard

AU - Pittelkow, Mark

AU - Hoppe, Richard

AU - Parker, Sareeta

AU - Geskin, Larisa

AU - Pinter-Brown, Lauren

AU - Girardi, Michael

AU - Burg, Günter

AU - Ranki, Annamari

AU - Vermeer, Maartan

AU - Horwitz, Steven

AU - Heald, Peter

AU - Rosen, Steve

AU - Cerroni, Lorenzo

AU - Dreno, Brigette

AU - Vonderheid, Eric C.

PY - 2011/6/20

Y1 - 2011/6/20

N2 - Mycosis fungoides (MF) and Sé zary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.

AB - Mycosis fungoides (MF) and Sé zary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.

UR - http://www.scopus.com/inward/record.url?scp=79959290992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959290992&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.32.0630

DO - 10.1200/JCO.2010.32.0630

M3 - Article

VL - 29

SP - 2598

EP - 2607

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -